Market Overview

BioAxone BioSciences' Scientific Advisory Board Member, Mark Bear, PhD, Receives $500,000 Beckman-Argyros Vision Research Award


Annual Award Recognizes Transformative Breakthroughs in Vision

BioSciences, Inc
., a biotechnology company focused on developing
innovative drugs to treat neurotrauma and neurovascular disorders, today
announced that its Scientific Advisory Board member, Dr. Mark Bear, the
Picower Professor of Neuroscience at the Massachusetts Institute of
Technology, received the prestigious Arnold and Mabel Beckman Foundation 2018
Beckman-Argyros Vision Research Award

This annual award recognizes an individual who has made and is
continuing to make significant, transformative breakthroughs in vision
research. Over several decades of research, Dr. Bear has made
significant contributions to understanding the mechanisms of synaptic
plasticity in the cerebral cortex. The award recognizes his work on the
visual cortex and childhood amblyopia, also called "lazy eye." Dr. Bear
and his team have shown that vision loss in the weak eye can be reversed
in multiple preclinical models of amblyopia, overturning the dogma that
the loss of vision is permanent. His findings have relevance to the
mechanisms of synaptic plasticity in general, including changes in
synaptic plasticity that occur in neurotrauma.

"We are delighted to see that Dr. Bear's decades of research on synaptic
plasticity is being honored by such an internationally recognized
organization," said Lisa McKerracher, PhD, CEO, BioAxone BioSciences.
"His expertise and counsel as one of our long-time scientific advisory
board members has been enormously valuable as we develop transformative
treatments for neurotrauma and neurovascular disorders."

About The Arnold and Mabel Beckman Foundation
Arnold and Mabel Beckman Foundation
provides grants to researchers
and non-profit research institutions in chemistry and life sciences to
promote scientific discoveries, and particularly to foster the invention
of methods, instruments, and materials that will open up new avenues of

About BioAxone BioSciences
BioAxone BioSciences is a
clinical-stage biotechnology company based in Cambridge, MA, and is
developing innovative drugs to restore neurological function for
patients with spinal cord injuries and neurovascular disorders. The
company also has preclinical programs in glaucoma and aimed at restoring
epithelial barriers in gastrointestinal disorders. BioAxone is led by a
team of scientists renowned for their work on axon regeneration,
diseases involving Rho/ROCK signaling and cell barrier function. For
more information, visit
and follow the company on Twitter at @BioAxone.

View Comments and Join the Discussion!